Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Cardiovasc Electrophysiol ; 31(7): 1848-1850, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32459024

RESUMEN

The role of left atrial appendage occlusion devices for stroke prevention in nonvalvular atrial fibrillation (AF) continues to expand. Device embolization is a rare but potentially catastrophic complication with variable clinical presentations. Here, we present a case of delayed dislodgment of a watchman device discovered on routine echocardiographic follow-up in a patient who later admitted to neurological symptoms. Urgent surgical device retrieval was performed with no further complications or neurological sequelae.


Asunto(s)
Apéndice Atrial , Fibrilación Atrial , Accidente Cerebrovascular , Anticoagulantes , Fibrilación Atrial/diagnóstico por imagen , Fibrilación Atrial/cirugía , Estudios de Seguimiento , Humanos , Accidente Cerebrovascular/diagnóstico por imagen , Accidente Cerebrovascular/etiología , Resultado del Tratamiento
2.
J Oncol Pharm Pract ; 25(8): 2045-2048, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30636528

RESUMEN

Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.


Asunto(s)
Atrios Cardíacos/efectos de los fármacos , Mieloma Múltiple/tratamiento farmacológico , Oligopéptidos/efectos adversos , Anciano , Cardiotoxicidad/etiología , Atrios Cardíacos/patología , Humanos , Masculino , Oligopéptidos/administración & dosificación
3.
Psychopharmacology (Berl) ; 182(3): 321-6, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16001113

RESUMEN

RATIONALE: Paroxetine may decrease mental stress-induced cardiovascular responses and so benefit individuals with heart disease, even those with no psychiatric illness. OBJECTIVES: The effects of paroxetine on cardiovascular measures during a speech task were evaluated in psychiatrically healthy subjects with a history of coronary artery disease (CAD). METHODS: Eight subjects completed this double-blind, placebo-controlled, cross-over study in which each subject took 1 month of paroxetine and 4 weeks of placebo in random order. While on each study, medication, blood pressure, heart rate, and plasma norepinephrine concentrations were measured during a period of relaxation and during a mental stressor. The mental stressor consisted of thinking about a stressful topic, speaking about the topic, and listening to a tape-recorded replay of the speech. RESULTS: While on paroxetine, systolic blood pressure and diastolic blood pressure were 10-15% lower (p < 0.005) during the stressor, relative to measures obtained while on placebo. Pulse and plasma norepinephrine concentrations during stress trended lower during paroxetine treatment but did not reach statistical significance. CONCLUSION: Paroxetine has antihypertensive properties during periods of psychological stress in psychiatrically healthy subjects with a history of CAD, and so should be evaluated for potential cardio-protective qualities.


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Enfermedad Coronaria/fisiopatología , Paroxetina/farmacología , Pulso Arterial , Estrés Psicológico/fisiopatología , Anciano , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Masculino , Norepinefrina/sangre
4.
Int J Infect Dis ; 9(6): 335-9, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16085441

RESUMEN

OBJECTIVES: Newer microbiologic methods to determine the species of coagulase-negative staphylococci (CoNS) have evolved which have shown that most endocarditis due to CoNS is caused by Staphylococcus epidermidis, and far fewer by Staphylococcus warneri and Staphylococcus lugdunensis. METHODS: The recent opportunity to successfully treat a patient with methicillin-resistant Staphylococcus capitis endocarditis secondary to an infected transvenous pacemaker led to a review of the literature relating to S. capitis endocarditis. RESULTS: Thirteen previously recorded patients were identified. Twelve (86%) patients were male. Ten had endocarditis associated with a native valve, two with prosthetic valves and one with a transvenous pacemaker. Mortality was low in all 14 cases (including this case report) with only two deaths; one in a patient with a native valve and the other with a prosthetic valve. Four of the isolates were methicillin resistant but sensitive to vancomycin, which was used in the treatment of eight patients. Those patients with prosthetic cardiac devices appear to do better when the devices are surgically removed. CONCLUSIONS: CoNS as a cause of endocarditis appears to be increasing and the current ability to determine the species of these organisms should elicit the epidemiology, clinical characteristics and biomolecular mechanisms involved in the induction of valvular disease.


Asunto(s)
Endocarditis Bacteriana/microbiología , Marcapaso Artificial/efectos adversos , Infecciones Relacionadas con Prótesis/microbiología , Infecciones Estafilocócicas/microbiología , Staphylococcus/aislamiento & purificación , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Staphylococcus/clasificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA